Drug Type Universal CAR-T |
Synonyms LMY-921 |
Target |
Mechanism BAFF-R inhibitors(B-cell activating factor receptor inhibitors), BCMA inhibitors(B-cell maturation protein inhibitors), TACI modulators(Tumor necrosis factor receptor superfamily member 13B modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Luminary Therapeutics, Inc.Startup |
Active Organization Luminary Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Malignant Neoplasm | Preclinical | US | Luminary Therapeutics, Inc.Startup | 10 Aug 2022 |